Imaging Advances in Bronchoscopy Through the Combination of High-Definition Bronchoscopes and New Image Processing Systems

Patient Characteristics

• The study is a technical note based on a series of five representative cases and does not involve a cohort of patients with defined characteristics.

Device

• CV-1500 (EVIS X1^TM endoscopy system) with image enhancement endoscopy (IEE) including Brightness Adjustment Imaging with Maintenance Contrast (BAI-MAC^TM) technology, Texture and Color Enhancement Imaging (TXI^TM) technology, and Red Dichromatic Imaging (RDI^TM) technology
• BF-H1200 (diagnostic –Outer diameter 4.9 mm; 2.2 mm working channel)
• BF-1TH1200 (therapeutic –Outer diameter 5.8 mm; 3.0 mm working channel)

Assessment

• The appearance of lesions and image quality with different imaging modes (RDI, TXI, BAI-MAC).

• RDI-1 identified superficial blood vessels associated with the lesion (B; yellow arrow)
• RDI-3 detected a deep vessel (C)
• This information guided site selection to a low-perfusion area (B; white arrow), and RDI-1 was then used to detect bleeding points (E)

Disclaimer: RDI technology is not intended to replace histopathological sampling as a means of diagnosis.

• Improved the visibility of subepithelial blood vessels (A vs. B)
• Blood vessels were easily distinguishable and recognized more three-dimensionally (C vs. D)

• With the use of the BAI-MAC function, the tracheal carina is clearly visible from above the trachea (A).
• In peripheral bronchial branches, BAI-MAC aids in correctly accessing the next bronchus (B).

Disclaimer: BAI-MAC technology is not intended to replace histopathological sampling as a means of diagnosis.

The integration of high-definition bronchoscopy with advanced image processing (RDI^TM, TXI^TM and BAI-MAC^TM technologies) shows potential for enhancing clinical knowledge and refining diagnostic strategies.

• The challenge of bronchoscopy for diagnosing malignant tumors is to sample viable cancer cells and avoid bleeding, a common sideeffect of bronchoscopy.
• RDI technology can assist in selecting optimal biopsy sites by identifying necrotic areas and regions with a high risk of bleeding, thus balancing the need to avoid bleeding while obtaining viable cancer cells.
• TXI technology provides a precise contrast on superficial blood vessels, even allowing the estimation of the depth of blood vessels.

This Study Overview is intended for educational and informational purposes only. It provides an objective summary of data from a single publication. It does not constitute a comprehensive literature review and should not be interpreted as a substitute for evaluating the full body of evidence on the topic. For complete methodology, results, and context, please refer to the original publication.

Contact Olympus Scientific Affairs at  SciA@olympus.com with any questions on this information.

Any content or information (“Content”) presented herein is illustrative in nature and does not guarantee or represent specific information, outcomes, or results. Olympus Medical Systems Corp. and its parents, subsidiaries, affiliates, directors, officers, employees, agents, and representatives (collectively “Olympus”) does not represent to or warrant the accuracy or applicability of the Content. Under no circumstances shall Olympus be liable for any costs, expenses, losses, claims, liabilities, or other damages (whether direct,indirect, special, incidental, consequential, or otherwise) that may arise from, or be incurred in connection with, the Content or any use thereof.
As medical knowledge is constantly growing, technical modifications or changes of the product design, product specifications,accessories, and service offerings may be required. Medical devices listed may not be available for sale in all countries.